Tocilizumab Associated With Survival in Patients Hospitalized for COVID-19 Acute Respiratory Distress Syndrome and Low Urine Output.
Raef Ali FadelAshley ScottAustin ParsonsIvanna MurskyjNour NasiriAlaa Abu SayfDaniel OuellettePublished in: Journal of intensive care medicine (2023)
In this retrospective cohort review of patients hospitalized with COVID-19 and moderate or severe ARDS, tocilizumab administration was independently associated with survival in patients with low urine output ≤ 0.7 mL/kg/h on the day of intubation. Prospective studies are needed to investigate the impact of urine output on efficacy of interleukin-targeted therapies in the management of ARDS.
Keyphrases
- acute respiratory distress syndrome
- end stage renal disease
- extracorporeal membrane oxygenation
- newly diagnosed
- coronavirus disease
- rheumatoid arthritis
- chronic kidney disease
- mechanical ventilation
- sars cov
- ejection fraction
- peritoneal dialysis
- cross sectional
- early onset
- juvenile idiopathic arthritis
- patient reported
- patient reported outcomes
- systemic lupus erythematosus
- free survival